CML
Conference Coverage
Dasatinib potentially a new SOC for children with CML-CP
CHICAGO—The largest ongoing and prospective trial of pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP), according to the...
News
Authority on hematologic malignancies dies
Physician, researcher, and educator H.
News
Single-cell analysis reveals TKI-resistant CML stem cells
Researchers say they’ve developed a technique for single-cell analysis that has revealed a population of treatment-resistant stem cells in...
News
Novel inhibitor proves ‘potent’ in hematologic malignancies
BOSTON—A pair of preclinical studies suggest the FLT3/BTK inhibitor CG’806 is active in a range of hematologic malignancies. In one of the...
From the Journals
High CD86+pDC counts may predict CML relapses
High CD86+pDC counts predicted relapses in chronic myeloid leukemia patients who stopped TKI therapy.
News
Scientists create online database to aid CML research
A newly launched online database provides researchers with access to data on gene expression in chronic myeloid leukemia (CML). The LEUKomics...
Conference Coverage
VIDEO: Careful TKI hiatus makes CML pregnancy possible
The scenario of a successful pregnancy in women with chronic myeloid leukemia has now played out several dozen times at a handful of U.S. centers...
News
Proteins may be therapeutic targets for TKI-resistant CML, ALL
Researchers say they have identified 2 signaling proteins that enable resistance to tyrosine kinase inhibitors (TKIs) and could be therapeutic...
News
Imatinib is safe, effective long-term, team says
Long-term follow-up of patients treated with imatinib suggests the drug can remain effective beyond 10 years and does not confer “unacceptable”...
From the Journals
In CML, imatinib benefits persist at 10 years
Researchers are now reporting the final follow-up results for the IRIS trial after a median of 10.9 years.
News
Acquired mutations may compromise assay
A newly discovered issue with the Ba/F3 transformation assay could “jeopardize attempts to characterize the signaling mechanisms and drug...